Malaria 2025: Accelerate to Eliminate The Global Technical Strategy for Malaria: Setting global targets Azra Ghani, GTS Steering Committee

Similar documents
Malaria 2025: Accelerate to Eliminate The Global Technical Strategy for Malaria:

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

A. Catalonia World Health Organization Demonstration Project

CHAPTER 2. HEALTH SERVICES

Commissioning Policy: South Warwickshire CCG (SWCCG)

Swindon Joint Strategic Needs Assessment Bulletin

Where do we stand today?

PMI End Use Verification (EUV) Survey Uganda 31 May 2016

Hospital Preparedness Checklist

TASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE

Response to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Diabetes Canada Pre-Budget Consultation Submission. Standing Committee on Finance and Economic Affairs. Government of Ontario.

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

Guidance for Applicants to the Global fund to Fight AIDS, TB and Malaria Round 8 Call for proposals 28 February 2008

Statement of Work for Linked Data Consulting Services

CDC Influenza Division Key Points November 7, 2014

CDC Influenza Division Key Points December 9, 2016

Vaccine Impact Modelling Consortium

CONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW

Chapter 6: Impact Indicators

WCPT awards programme 2015

UNIT 2: mapping bananas

CDC Influenza Technical Key Points February 15, 2018

Lancet Special Issue on HIV in Men who have Sex with Men (MSM)

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

The data refer to persons aged between 15 and 54.

The principles of evidence-based medicine

FIGHT DEMENTIA ACTION PLAN

Frequently Asked Questions: IS RT-Q-PCR Testing

Evaluation of Hunter & New England HealthPathways

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES

This information shows what new challenges are likely to require prevention efforts moving forward.

MSF Alert! 5 epidemics to watch in 2016

Palliative Medicine Specialist

Catherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria

Career Confidence. by Kevin Gaw

Cardiac Rehabilitation Services

MGPR Training Courses Guide

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.

Module 6: Goal Setting

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

President Chirac understood that fighting disease is not just health systems and hospitals, it is about people. We must place people at the centre.

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Regulatory forum for manufacturers

New London County Unified Intake for Homeless Families

Attachment 3. Efforts to Address the Opioid Epidemic in Clark County

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

PET FORM Planning and Evaluation Tracking ( Assessment Period)

TERMS OF REFERENCE (ToR) NATIONAL INDIVIDUAL CONSULTANCY

Persistence Market Research

World Confederation for Physical Therapy Congress , May Singapore

CLINICAL MEDICAL POLICY

Patterns of Cholesterol Distribution in the Participants of a Screening Project

Pain Management Learning Plan

Ontario 2018 provincial election issues backgrounder

Exclusion of Key Populations and People Living with HIV from implementation of programmes 10 June To: CC:

LTCH QUALITY REPORTING PROGRAM

Preventing and Responding to Emerging IDs the role of WHO

US Public Health Service Clinical Practice Guidelines for PrEP

TO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:

Pandemic H1N1 2009: DrillSafe Update. David Blizzard BD Manager, Energy Mining and Infrastructure

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA

Obesity/Morbid Obesity/BMI

FOUNDATIONS OF DECISION-MAKING...

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

Interpretation. Historical enquiry religious diversity

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

Agenda Item 3 CX/FL 17/44/3 Add 1 September 2017

Strategic Plan Publication No: EO-SP

Health action in crisis

Osteoporosis Fast Facts

Risk factors in health and disease

Catherine Worthingham Fellows of the APTA Instructions for Nominators

77 WHO/IPA workshop on Immunisation

Medical Director of Palliative Care INFORMATION PACK

RI International Peer Employment Training

TB/HIV in the Americas Review of Progress, Barriers and Successes

A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation

Cancer Association of South Africa (CANSA)

Who is eligible for LifeCare? What services are available?

Safety of HPV vaccination: A FIGO STATEMENT

Summary Report. Introduction and setting the scene Autilia Newton, Public Health England, Health & Justice Acting Deputy Director

Electrosurgical Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking

Using Causal Inference To Make Sense of Messy Data

STAKEHOLDER IN-DEPTH INTERVIEW GUIDE

iprex Fact Sheet: Key Results

MANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27)

Primary Health Networks Greater Choice for At Home Palliative Care Central Queensland Wide Bay Sunshine Coast PHN

FTD RESEARCH: The Value of Studies and Opportunities for Involvement

Amniotic Membrane Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Transcription:

Malaria 2025: Accelerate t Eliminate The Glbal Technical Strategy fr Malaria: 2016-2025 Setting glbal targets Azra Ghani, GTS Steering Cmmittee Geneva, 12 March 2014 1

Visin and Gals Purpse f Visin and Gals sectin This sectin is cre t the GTS, by setting the directin and prviding cncrete targets that the malaria cmmunity shuld aim fr in the cming decade Visin and Gals prvide the strategic frame t reginal and lcal level prgrammes when develping their wn strategies Key questins Are the prpsed visin / gals sufficiently aggressive and ambitius t drive change and accelerate impact in the cming decade? Is the verall strategic frame clear, cnsistent, and cmprehensive? 2

Visin and Gals Lngterm Visin A single visin: a wrld free f malaria GTS Visin T accelerate prgress t a wrld free f malaria Gal 1 t reduce malaria mrtality rates glbally by 75% cmpared t 2015 Gals Gal 2 t reduce malaria case incidence glbally by 75% cmpared t 2015 Gal 3 t eliminate* malaria frm 20** cuntries that had nging transmissin f malaria in 2015 *eliminate refers t n indigenus transmissin f malaria; nt certificatin ** 20 cuntries t be cnfirmed 3

Fcus n malaria targets Three cmbined appraches t define apprpriate target levels 1 Reginal / Cuntry level targets Imperial Cllege malaria transmissin mdel GTS targets 2 3 GMP malaria eliminatin trend analysis Target setting methdlgy t be detailed in a separate Annex f the GTS dcument 4

Eliminatin gals & targets 2016-2030 as stated by cuntries 2015 Zer indigenus cases: Btswana Swaziland Indnesia (337 districts) Ethipia (specific gegraphical areas) 2017 Zer indigenus cases: China Zanzibar 2025: Zer indigenus cases: Cambdia Iran India (5-10 States) 2030: Zer indigenus cases in Indnesia 2016 Zer indigenus cases: Bhutan Thailand (60% f districts) Slmn Islands (Temtu Prvince) Vanuatu (1 Prvince) 2018: Zer indigenus cases: Suth Africa 2020: Zer indigenus cases: China Djibuti Malaysia Suriname Yemen Philippines (pst 2020) Thailand (80% f districts) Indnesia (459 districts) 2026: Zer indigenus cases in Nepal 5

Trend Analysis What have cuntries achieved t date? Hw des this match the resurces that have been input? Data cmpiled frm 2013 Wrld Malaria Reprt Trends in P.falciparum and P.vivax case reprts frm 2000 nwards Changing cverage f LLINs and IRS Increase in access t first-line treatment with ACTs Predictins fr 2016-2025: Statistical trend extraplatin (all cases) Mathematical mdel fitting (P.falciparum nly) 6

P.f cases P.v cases Example Trends: Bhutan Prgram Gals: T achieve zer indigenus case f malaria in Bhutan by 2016 100% 80% 60% 40% LLIN cverage IRS cverage 20% 0% 25,000 20,000 2000 2005 2010 25,000 20,000 15,000 10,000 15,000 10,000 Data falciparum Data vivax 5,000 5,000-2000 2005 2010 7 -

P.f cases P.v cases Example Trends: India Prgram Gals: substantial and sustained reductin in the burden f malaria in the near and mid-term; eliminatin f malaria in the lng term 30% 25% 20% 15% 10% LLIN cverage IRS cverage 5% 0% 1,400 2000 2005 2010 1,400 1,200 1,200 1,000 1,000 800 600 400 800 600 400 Data falciparum Data vivax 200 200-2000 2005 2010-8

P.f cases P.v cases Example Trends: Brazil Prgram Gals: Reductin in mrtality, cases and transmissin 100% 80% 60% 40% LLIN cverage IRS cverage 20% 0% 3,500 2000 2005 2010 12,000 3,000 2,500 2,000 1,500 1,000 500 10,000 8,000 6,000 4,000 2,000 Data falciparum Data vivax - 2000 2005 2010-9

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Number f cases Prjecting Frwards: Statistical Mdels Statistical mdels assume a cntinued trend Difficult t knw which functin is mst apprpriate Different functins give very different predictins 9,000 8,000 7,000 Observed Expnential decay Hlt-Winters Quadratic functin Linear (Observed) 6,000 5,000 (Bhutan) 4,000 3,000 2,000 1,000-10

Prjected decreases fr cuntries in which it is pssible t assess trends 12 12 10 10 8 8 6 6 4 4 2 2 0 0 African African Regin f the Americas Regin Eastern f Mediterranean the Americas Eastern Eurpean Mediterranean Eurpean Suth-East Asia Suth-East Western Pacific Asia Western Pacific % reductin 2016-2025 % reductin 2016-2025 Median decrease 82% (IQR 59%-99%) r 73% (IQR 55%-89%) excluding Eurpean Regin 11

P.f cases P.f cases Prjecting Frwards: Mathematical Mdels Can predict varied trends depending n cverage f interventins Less easy t match past trends P.falciparum nly Bhutan India 25,000 1,600 20,000 1,400 1,200 15,000 1,000 10,000 800 600 Data falciparum Mdeled falciparum 5,000 400 200-2000 2005 2010 2015 2020 2025-2000 2005 2010 2015 2020 2025 12

Mdelling scenaris fr P.falciparum (Wrk in Prgress) Aim t use mathematical mdel f malaria transmissin t assess what impact cmbinatins f currently recmmended interventins culd have if implemented between 2016 and 2025 Mdel inputs: Endemicity in 2010 (MAP prevalence and WMR 2013 case reprts) Cverage f interventins (treatment, ACT use, LLINs and IRS) up t 2012 (WMR 2013 & DHS/MIS surveys) Vectr species & their binmics fr 3 mst cmmnly reprted species in a cuntry (MAP estimates) Mdel utputs: Estimates f percentage change in cases and deaths between 2016 and 2025 Prprtin f cuntries achieving different reductin threshlds Prprtin f cuntries mved int pre-eliminatin status (<1 case per 1000 ppulatin per year) 13

Scenaris Scenari Descriptin 1 Cntinue the current cverage f LLINs, IRS and access t treatment 2 Increase universal cverage f LLINs t 80%, access t treatment t 80% f all cases (r existing cuntry levels if greater), all cases accessing care are treated with an apprpriate ACT 3 Scenari 2 plus SMC t children aged 3 mnths t 5 years with SP plus amdiaquine in recmmended areas in the Sahel regin f Africa at 80% cverage 3a Scenari 2 plus IPTi t infants with SP in Africa at 80% cverage where the EIR is abve 10 ibpppy 4 Scenari 3 plus treatment f severe disease with IV artesunate (assumed t reduce mrtality in cases wh reach hspital by a further 20%) 5 Scenari 4 plus yearly IRS with DDT (at 80% cverage) in thse cuntries in which a 90% reductin in cases r a mrtality rate less than 1 death per 1000 ppulatin per year was nt achievable by 2025 with Scenari 4 6 Scenari 5 with increased cverage f LLINs t 90%, access t treatment t 90% f all cases, all cases accessing care are treated with an apprpriate ACT 14

Case incidence per persn per year Glbal Prjectins: Cases (A) 0.3 1. Cntinue as in 2012 0.25 0.2 0.15 0.1 0.05 0 2000 2005 2010 2015 2020 2025 2. Increase t 80% cverage f LLINs and treatment 3. Plus SMC at 80% cverage in recmmended areas 3a. Plus IPTi t infants with 80% cverage in Africa 5. Plus yearly IRS at 80% cverage in areas nt achieving gals 6. All interventins at 90% cverage Past scale-up (B) 1 1. Cntinue as in 2012 15

Deaths per 1000 peple per year Case 0.05 Glbal Prjectins: Deaths 0 2000 2005 2010 2015 2020 2025 achieving gals 6. All interventins at 90% cverage Past scale-up (B) 1 1. Cntinue as in 2012 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 2000 2005 2010 2015 2020 2025 2. Increase t 80% cverage f LLINs and treatment 3. Plus SMC at 80% cverage in recmmended areas 3a. Plus IPTi t infants with 80% cverage in Africa 4. Plus treatment f severe disease with IV artesunate 5. Plus yearly IRS at 80% cverage in areas nt achieving gals 6. All interventins at 90% cverage Past scale-up 16

Predicted Glbal Reductins t 2025 Scenari % Reductin in Cases % Reductin in Deaths 2. Increase t 80% 44.6% 53.4% 3. Scenari 2 plus SMC 45.7% 54.6% 3a. Scenari 2 plus IPTi 44.6% 53.4% 4. Scenari 3 plus treatment f severe disease with IV artesunate 45.7% 57.2% 5. Scenari 4 plus yearly IRS (currently with DDT at 80% cverage) 82.5% 81.7% 6. Scenari 5 with increased cverage t 90% 88.6% 88.5% 38 ut f 80 cuntries predicted >90% reductin in cases under Scenari 5 Substantial reginal variatins: >95% reductin in cases and deaths under Scenari 5 in EMRO, SEARO and PAHO 27 cuntries at pre-eliminatin by 2025 under current cverage Additinal 16 cuntries predicted t reach this under Scenari 5 17

Resurce Needs Mdel tracks resurces utilised, taking int accunt ppulatin distributins in at-risk areas and ppulatin grwth Includes interventin resurces and healthcare utility (assuming n change in health-seeking behaviur) DHS/MIS surveys used t estimate rates f NMFI in children under 5 t calculate RDT resurces (ther methds will be cnsidered) IPTp csts nt currently incrprated (but can be) Financial and prgramme csts based n recent reviews Additinal malaria cntrl prgram csts (training/cmmunicatin, CHWs, peratinal research/m&e, infrastructure/institutinal strengthening) currently added using previus GMAP methdlgy 18

Resurce Csts Cst (USD 2010)* GMAP assumptins LLIN (per net) $7.03 $6.41 IRS (per persn) $3.60 $7.50 SMC (per curse) $1.50 - ACT treatment fr uncmplicated malaria at health centre / utpatient Nn-ACT treatment fr uncmplicated malaria at health centre / utpatient $1.00 (ACT cst) $0.60 (RDT cst) $1.40 (healthcare visit cst) $0.30 (drug cst) $0.60 (RDT cst) $1.40 (healthcare visit cst) $1.08 (paediatric) $2.025 (adult) $0.30 RDTs used fr NMFI (per fever) $0.60 $0.78 Hspital csts assciated with treatment f severe disease (assumed t be the same fr quinine and artesunate) $30.26 $29.50 19

Preliminary Estimates Scenari Estimated Cst per Year (2010 US$) including healthcare csts Estimated Cst per Year (2010 US$) excluding healthcare csts 1. Remain at current levels 2.0 billin 1.7 billin 2. Increase t 80% 3.1 billin 2.7 billin 3. Scenari 2 plus SMC 3.2 billin 2.9 billin 4. Scenari 3 plus treatment f severe disease with IV artesunate 3.2 billin 2.9 billin 5. Scenari 4 plus yearly IRS with DDT (at 80% cverage) 5.5 billin 5.4 billin 6. Scenari 5 with increased cverage t 90% 6.1 billin 6.0 billin Cmparative Figures: 2013 internatinal disbursements: US$ 1.97 billin (WMR 2013) 2012 dmestic spend: US$ 522 millin (WMR 2013) Original GMAP estimates:* $5.1 billin per year frm 2011 t 2020 *Includes LLINs, IRS, IPTp and treatment and management f cases assuming 100% cverage 20

Summary Gal 1 t reduce malaria mrtality rates glbally by 75% cmpared t 2015 Natinal Plan Review: 50%, 70%, 75%, 90% reductins Mdelling: 55%-90% reductin Gal 2 t reduce malaria case incidence glbally by 75% cmpared t 2015 Gals Natinal Plan Review: 50%, 70%, 75%, 90% reductins r threshld incidence Trend Analysis: 73% / 82% reductin Mdelling: 45%-88% reductin Gal 3 t eliminate* malaria frm 20** cuntries that had nging transmissin f malaria in 2015 Natinal Plan Review: 15 cuntries have cmplete r partial eliminatin currently in plan Mdelling: 27 cuntries at pre-eliminatin threshld by 2025, additinal 16 culd reach this with intensive scenari 21